METABOLIC DISORDERS IN PATIENTS WITH ONCOLOGIC PATHOLOGY

Relevance: Metabolic disorders often take on a systemic character. It affects carbohydrate, lipid, and hormonal metabolism. Moreover, these changes promote the development and aggravation of several pathologies. The prevalence of metabolic disorders, including obesity, is increasing worldwide and in Kazakhstan. The study focused on the clinical characteristics of metabolic syndrome (MS) components in patients with cancer comorbidities. Methods: The materials included medical records of cancer patients with MS – 35 people (main group) and non-cancerous patients with MS – 35 people (control group). MS was diagnosed with a combination of three symptoms: abdominal obesity, high blood pressure, and increased high-density lipoprotein cholesterol (HDL-C) levels. The data were analyzed and processed using the STATIS-TICA 10 software package. The significance criterion was p<0.05. Results: All studied patients were diagnosed with abdominal obesity. Indicators analysis showed a significant difference in HDL-C concentration in the main and control groups: 3.8 mmol/L in cancer patients and 5.7 mmol/L in the controls. No significant difference in blood pressure was found. Conclusion: The age of patients with MS evidences a threatening tendency to develop metabolic disorders in young and middle ages. A significantly lower concentration of LDL-C in cancer patients compared with the controls allows using this parameter to predict cancer ]development in patients diagnosed with MS. Thus, HDL-C concentration could be used as a metabolic marker for pre-symptomatic diagnostics.